No Data
Wanbang Pharmaceutical (301520.SZ): Hefei Quanxiang plans to participate in a 10 million yuan private equity fund investment, laying out the field of cell and gene industry.
Wanbang Medicine (301520.SZ) announced that the Hefei Qunxiang Qiming Enterprise Management Partnership (Limited Partnership) controlled by the company...
万邦医药 (301520.SZ): The company-controlled partnership enterprise proposes to subscribe for private equity fund shares.
Gelonghui, November 26th - Wanbang Pharmaceutical (301520.SZ) announced that Hefei Qunxiangqiming Enterprise Management Partnership Enterprise (Limited Partnership) controlled by the company, referred to as "Hefei Qunxiang", signed the "Shenzhen Songhe Cell and Gene Industry Private Equity Fund Partnership Enterprise (Limited Partnership) Partnership Agreement" and related documents with Shenzhen Songhe Capital Management Co., Ltd. on November 22, 2024. Hefei Qunxiang, as a limited partner, subscribed to the Shenzhen Songhe Cell and Gene Industry Private Equity Fund Partnership Enterprise (Limited Partnership) (tentatively named, finally approved by the industrial and commercial registration authority as
Wanbang Pharmaceutical: Report for the third quarter of 2024
Express News | Wanbang Pharmaceutical: Intends to repurchase shares amounting to 15 million yuan to -30 million yuan.
About 5.4068 million restricted shares of Wanbang Medicine (301520.SZ) will be listed for trading on September 25th.
Wanbang Pharmaceutical (301520.SZ) announced that the shares to be released from restriction this time were issued before the company's initial public offering...
Anhui Wanbang Pharmaceutical Technology: Half-year report for the year 2024.
No Data
No Data